Background: Edoxaban, an oral factor Xa inhibitor with 50% renal clearance, was noninferior to well-managed warfarin for stroke or systemic embolism (S/SE) prevention and reduced bleeding in patients with atrial fibrillation. We evaluated the efficacy and safety of edoxaban versus warfarin across the range of baseline creatinine clearance (CrCl) in the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48) with a focus on the higher-dose edoxaban regimen (HDER) and the upper range of CrCl.
e doxaban is a direct oral factor Xa inhibitor that is 50% renally cleared. 1 The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48) evaluated the long-term efficacy and safety of 2 dosing regimens of edoxaban versus warfarin in patients with atrial fibrillation (AF) at moderate to high risk of stroke. 2 Overall, the higher-dose edoxaban regimen (HDER) was noninferior to warfarin for the prevention of thromboembolic events and significantly reduced major bleeding, leading to regulatory approval of the HDER for use in AF in several countries. 3, 4 As a result of the significant (50%) renal clearance of edoxaban, patients with severe renal dysfunction, defined by a creatinine clearance (CrCl) <30 mL/min, were excluded from ENGAGE AF-TIMI 48. Furthermore, on the basis of pharmacokinetic modeling and simulation, patients with moderate renal dysfunction (CrCl, 30-50 mL/ min) and low body weight or concomitant use of a potent phosphorylated glycoprotein inhibitor received a 50% reduction in the edoxaban dose. 5 In this prespecified analysis, we evaluate the efficacy, safety, and net clinical outcomes with HDER compared with warfarin across the range of baseline renal functions in patients in the ENGAGE AF-TIMI 48 trial with a focus on the patients with a CrCl >95 mL/min. This analysis is of particular interest in light of the US Food and Drug Administration label that restricts use in patients with a CrCl >95 mL/min because of concerns of decreased relative efficacy for the prevention of ischemic stroke compared with warfarin. 3 
MethOds study Population
The ENGAGE AF-TIMI 48 trial was a multinational, randomized, double-blind, double-dummy trial comparing 2 dosing regimens of edoxaban with warfarin. 2, 6 Eligible patients were ≥21 years of age with AF within 12 months and a CHADS 2 risk score ≥2. Key exclusion criteria included a CrCl <30 mL/min estimated with the Cockcroft-Gault method, a high risk of bleeding, and the use of dual antiplatelet therapy. The ethics committee at each participating center approved the protocol. Written informed consent was obtained from all patients.
randomization and study drugs
Patients (n=21 105) were randomly assigned in a 1:1:1 ratio to receive warfarin, an HDER (60 mg daily or 30 mg daily if a dose reduction was required), or a lower-dose edoxaban regimen (LDER; 30 mg or 15 mg daily if a dose reduction was required). The dose of edoxaban was reduced by 50% if any of the following were present at screening or during the course of the trial: CrCl of 30 to 50 mL/min, body weight ≤60 kg, or use of a potent phosphorylated glycoprotein inhibitor (ie, verapamil, quinidine, or dronedarone). 5 The assignment of dose reduction at randomization for renal impairment (CrCl, 30-50 mL/min) was determined from CrCl estimates collected during screening. Thus, there was a cohort of subjects with a CrCl ≤50 mL/ min at randomization who did not undergo dose reduction as a result of a screening CrCl >50 mL/min (n=544). Warfarin was dose adjusted to an international normalized ratio of 2.0 to 3.0. To maintain blinding, sham international normalized ratio values were generated for patients assigned to edoxaban. Randomization was stratified according to the risk of stroke (CHADS 2 score of 2-3 versus 4-6) and the need for a reduction in the dose of edoxaban at the time of randomization.
The analysis described here focuses primarily on the comparison of warfarin with the HDER because this is the regimen approved for use in AF. 3, 4 Data for the LDER are included in the Appendix in the online-only Data Supplement.
end Points
The primary efficacy end point, the composite of all stroke (ischemic or hemorrhagic) or systemic embolism (S/SE), was assessed from the time of randomization until the first occurrence of one of the events. The primary safety end point was the time to the first occurrence of major bleeding as defined by the International Society on Thrombosis and Haemostasis. 7 The primary net clinical outcome was the time to first occurrence of clinical Perspective
What is new?
• We evaluated outcomes with edoxaban, an oral factor Xa inhibitor with 50% renal clearance, versus warfarin by baseline creatinine clearance (CrCl) in ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial FibrillationThrombolysis in Myocardial Infarction Study 48). • In the prespecified subgroups (CrCl 30-50 and >50 mL/min), the higher-dose edoxaban regimen was comparable to warfarin for preventing stroke or systemic embolism and resulted in significantly less major bleeding.
• Exploratory analyses suggested lower relative efficacy for the prevention of stroke or systemic embolism with the higher-dose edoxaban regimen compared with warfarin in the upper range of CrCl beyond ≈95 mL/min. Because of the lower rates of major bleeding, the net clinical benefit was more favorable with higher-dose edoxaban regimen across the range of CrCl.
What are the clinical implications?
• Edoxaban demonstrated superior safety and comparable efficacy to warfarin for the prevention of thromboembolic events in many patients with atrial fibrillation. However, for edoxaban and possibly other non-vitamin K antagonist oral anticoagulants with significant renal clearance, the optimal dosing in the higher range of CrCl warrants further investigation.
an event in the composite of S/SE, major bleeding, or all-cause death. 6 Other net clinical end points studied included severe or irreversible events, that is, the composite of disabling stroke, life-threatening bleeding, or all-cause death and the composite of disabling stroke, life-threatening bleeding, myocardial infarction, or all-cause death. A sensitivity analysis for net clinical benefit was performed using a previously described method that compares rates of thromboembolism versus intracranial hemorrhage by treatment, including a 1.5-fold higher impact weighting for intracranial hemorrhage. 8 For this analysis, the net clinical benefit of HDER was defined as follows: (rate of S/SE in warfarin−rate of S/SE in HDER)−1.5×(rate of intracranial hemorrhage in HDER−rate of intracranial hemorrhage in warfarin). Details of the end point definitions are provided in the protocol. 2 
statistical analysis
The primary efficacy and net clinical outcome analyses were by intention to treat using Cox proportional hazards modeling with randomization treatment as a covariate and included events that occurred during the overall study period. Safety analyses included all patients given at least 1 dose of study drug and events occurring during the on-treatment period, defined as the time between the first dose and the last dose of study drug plus 3 days, with interval censoring of events during study-drug interruptions lasting >3 days. Additional sensitivity analyses were performed for the primary efficacy end point using the modified intention-to-treat population (all randomized patients who received at least 1 dose of study drug) during the ontreatment period with interval censoring as described.
The subgroup analysis by baseline renal function was prespecified for the cut point of 50 mL/min for CrCl with the Cockcroft-Gault formula, the threshold for edoxaban dose reduction by renal criteria. Exploratory subgroup analyses were performed using additional cut points defined by estimated renal clearance using the Cockcroft-Gault formula and the CKD-EPI ( Chronic Kidney Disease Epidemiology Collaboration) equation. 9, 10 For the purposes of this analysis, the subgroup with severe renal dysfunction is defined by a CrCl <30 mL/min at randomization; moderate renal dysfunction, by a CrCl of 30 to 50 mL/min; mild renal dysfunction, by a CrCl >50 to 95 mL/ min; mild or no renal dysfunction, by a CrCl >50 mL/min; and normal renal function, by a CrCl >95 mL/min. We assessed for heterogeneity using Cox proportional hazard modeling including a treatment-by-renal subgroup interaction term.
Although severe renal disease was exclusionary, 163 patients (0.7%; warfarin, n=52; HDER, n=68; LDER, n=43) were randomized despite a CrCl <30 mL/min using the Cockcroft-Gault estimate at the time of randomization and are included in the moderate renal dysfunction subgroup for this analysis. A sensitivity analysis was performed comparing warfarin and HDER that excluded patients with a CrCl <30 mL/ min (n=120) and those with a randomization CrCl of 30 to 50 mL/min who did not undergo dose reduction secondary to a screening CrCl >50 mL/min (n=544). Event rates are expressed per 100 patient-years. All reported P values are 2-sided. Values of P<0.05 were considered to signify nominal statistical significance with no adjustment for multiple comparisons. All analyses were conducted with Stata/IC version 13.1 (StataCorp LP) or SAS version 9.3 (SAS Institute).
edoxaban Plasma concentrations
Trough blood samples were collected in 2725 subjects on treatment with the HDER 1 month after randomization (median time from preceding dose, 20 hours; interquartile range, 15-24 hours). Plasma concentrations of edoxaban were measured by Quintiles Bioanalytical and ADME Laboratories as described. 11 
results

Patient Population
The ENGAGE AF-TIMI 48 study randomized 21 105 patients who were followed up for a median of 2.8 years (interquartile range, 2.4-3.2 years). Of the 14 071 patients in the warfarin and HDER arms (excluding 7034 patients randomized to LDER), 2740 (19.5%) had a CrCl of ≤50 mL/min, 8208 (58.3%) had a CrCl >50 to 95 mL/min, and the remainder (n=3123, 22.2%) had a CrCl >95 mL/min at the time of randomization ( Table 1 ). The baseline characteristics were well balanced between the warfarin and HDER arms within each renal function subgroup. In contrast, baseline characteristics differed significantly across renal function subgroups (Table 1) . Patients with moderate renal dysfunction (CrCl, 30-50 mL/min) were older, were more often female, and had lower body weight and higher rates of established cardiovascular disease compared with patients with mild renal dysfunction (CrCl >50-95 mL/min) or normal renal function (CrCl >95 mL/min; P<0.05 for all). The risk of thromboembolic and bleeding events, as estimated by mean CHADS 2 , CHA 2 DS 2 -VASc, and HAS-BLED scores, was lowest in those with a CrCl >95 mL/min (P<0.05 for all). Eighty-four percent of patients with a CrCl of 30 to 50 mL/min at randomization underwent a 50% dose reduction on the basis of screening assessments, whereas only 14% and 4% of those with a CrCl of >50 to 95 and >95 mL/min, respectively, required a dose reduction at randomization. Rates of prior vitamin K antagonist therapy and baseline antiplatelet use were similar across all renal subgroups (P>0.05). Of note, the median time in therapeutic range on warfarin was lower in those with a CrCl of 30 to 50 mL/min (time in therapeutic range: 66.9% for CrCl ≤50 mL/min, 68.9% for CrCl >50-95 mL/min, and 68.2% for CrCl >95 mL/min; P<0.05).
Outcomes by Prespecified renal subgroups using the cockcroft-gault Formula
The relative efficacy, safety, and net clinical benefit of HDER compared with warfarin were consistent with the overall trial findings when evaluated by the prespecified renal subgroups defined by moderate renal dysfunction (CrCl 30-50 mL/min), in which most patients underwent edoxaban dose reduction, and mild or no renal dysfunction (CrCl >50 mL/min; Figure 1 ) at baseline. BMI indicates body mass index; CHF, congestive heart failure; CrCl, creatinine clearance; CVD, cerebrovascular disease; IQR, interquartile range; PAD, peripheral arterial disease; TIA, transient ischemic attack; and VKA, vitamin K antagonist. Modified HAS-BLED incorporates standard score variables except for labile international normalized ratio, resulting in a maximum score of 8. Baseline characteristics were well matched (P>0.05) by randomization in patients allocated to high-dose edoxaban regimen (HDEF) and to warfarin except for clinically minimal differences in the rate of dose reduction for CrCl of 30-50 mL/min (HDER, 78% versus warfarin, 81%) and low body weight (29% versus 33%) within the CrCl of 30 to 50 mL/min subgroup, BMI (30 versus 29 kg/m 2 ) in the CrCl >50 mL/min subgroup, and median age (73 versus 72 years) in the CrCl >50 to 95 mL/min subgroup. P<0.05 for all variables for comparison across CrCl subgroups except the rate of dose reduction for potent phosphorylated glycoprotein inhibitors, prior VKA use, and baseline aspirin or thienopyridine use.
Specifically, the absolute rates of the primary efficacy end point of S/SE were higher in both treatment arms in patients with moderate renal dysfunction at baseline (2.3%/y for HDER and 2.7%/y for warfarin) compared with those with mild or no renal dysfunction (1.4%/y for HDER and 1.6%/y for warfarin). The efficacy of HDER was similar to that of warfarin for the prevention of S/SE in the prespecified renal subgroups with no modification of the treatment effect by renal function (CrCl of 30-50 mL/min: hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.65-1.18; CrCl >50 mL/min: HR, 0.87; 95% CI, 0.72-1.04; P for interaction=0.94; Figure 1 ). Similarly, the absolute rates of International Society on Thrombosis and Haemostasis major bleeding were higher in those with moderate renal dysfunction at baseline (4.0%/y for HDER and 5.3%/y for warfarin) compared with those with mild or no renal dysfunction (2.5%/y for HDER and 3.1%/y for warfarin). HDER was superior to warfarin for the primary safety end point in both renal subgroups with no modification of the treatment effect by renal function (CrCl of 30-50 mL/min: HR, 0.76; 95% CI, 0.58-0.98; CrCl >50 mL/min: HR, 0.82; 95% CI, 0.71-0.95; P for interaction=0.62; Figure 1 ). Finally, those with moderate renal dysfunction at baseline were at higher risk for the primary net clinical outcome of S/SE, major bleeding, or death (CrCl of 30-50 mL/min: 11.4%/y for HDER and 13.4%/y for warfarin; CrCl >50 mL/min: 6.3%/y for HDER and 7.0%/y for warfarin; Figure The sensitivity analysis excluding subjects with a randomization CrCl <30 mL/min or a CrCl of 30 to 50 mL/ min who did not undergo dose reduction at randomization (because of a screening CrCl >50 mL/min) demonstrated consistent findings with comparable efficacy, superior safety, and a more favorable net clinical outcome for HDER compared with warfarin ( Figure I in the online-only Data Supplement).
The findings from comparisons of LDER and warfarin were also consistent with the overall trial results, with no effect modification by treatment for the primary efficacy (P for interaction=0.53), safety (P for interaction=0.11), or net clinical (P for interaction=0.42) end points for the prespecified subgroups with a CrCl of 30 to 50 and >50 mL/min (Figure II in the online-only Data Supplement). Specifically, in both subgroups, there was an unfavorable trend for the prevention of S/SE with LDER versus warfarin and a significantly lower relative risk of major bleeding and the net clinical outcome of S/SE, major bleeding, or death.
analysis of efficacy in Patients With Mild or no renal dysfunction
To evaluate whether there is differential relative efficacy of HDER compared with warfarin in patients with mild or no renal dysfunction (CrCl >50 mL/min), exploratory subgroups were defined by 15 mL/min increments of CrCl above the prespecified cut point of 50 mL/min using the Data for the efficacy and net clinical outcome analyses are from the intention-to-treat population for the overall study period. Data for safety are from the safety cohort for the treatment period with interval censoring of events during study-drug interruptions that lasted >3 days. CrCl (mL/min) at randomization was estimated with the Cockcroft-Gault equation. CI indicates confidence interval; HDER, higher-dose edoxaban regimen; HR, hazard ratio; P-int, P for interaction for treatment by renal subgroup; and S/SE, stroke or systemic embolism. *HDER of 60 mg daily or 30 mg daily if dose reduced for creatinine clearance (CrCl) ≤50 mL/min, weight ≤60 kg, or potent phosphorylated glycoprotein inhibitor use.
Cockcroft-Gault method ( Figure 2 ). The rate of S/SE generally decreased as renal function improved in both treatment arms. A significant treatment interaction was observed (P for interaction=0.03 for renal subgroups by 15 mL/min increments of CrCl by treatment) in which those with the highest baseline CrCl had lower relative efficacy of HDER compared with warfarin for the prevention of S/SE. Specifically, a significantly favorable effect was observed with HDER at low levels of CrCl that reversed to an unfavorable but nonsignificant effect at higher levels of CrCl, for which there were generally fewer events. Evaluating the rate of S/SE by CrCl as a continuous variable showed that the estimated event rate for HDER was similar to warfarin at a CrCl of ≈90 mL/min and surpasses that of warfarin at higher CrCls (P for interaction=0.01 for CrCl as a continuous variable by treatment; Figure IIIA in the online-only Data Supplement). On the basis of prior observations correlating trough edoxaban concentrations, anti-Xa activity, and outcomes, median on-treatment trough edoxaban concentrations were evaluated over the range of mild or no renal dysfunction (Figure 3) . 11 There was a significant inverse relationship between median trough edoxaban concentration and renal clearance (P for trend <0.001), with the most apparent decrease in concentrations occurring in the CrCl range of 90 to 110 mL/min.
On the basis of these collective findings and the current US Food and Drug Administration labeling for edoxaban that restricts use in patients with a CrCl >95 mL/ min, subsequent subgroup analyses used an exploratory CrCl cut point of 95 mL/min in addition to the prespecified cut point of 50 mL/min. 3 Outcomes by exploratory renal subgroups using the cockcroft-gault Formula An evaluation of the 3 subgroups defined by CrCl of 30 to 50, >50 to 95, and >95 mL/min found a nonsignificant trend toward differential relative efficacy for the primary end point with HDER versus warfarin across renal subgroups, with the lowest relative efficacy observed in those with a CrCl >95 mL/min (CrCl of 30-50 mL/min: HR, 0.87; 95% CI, 0.65-1.18; CrCl >50-95 mL/min: HR, 0.78; 95% CI, 0.64-0.96; CrCl >95 mL/min: HR, 1.36; 95% CI, 0.88-2.10; P for interaction=0.08 for the 3 renal function subgroups by treatment; Figure 4A and Table 2 ). Absolute event rates were very low in those with a CrCl >95 mL/min in both treatment groups (1.1%/y for HDER and 0.8%/y for warfarin), in whom the mean CHADS 2 score was 2.6 (±0.8) and warfarin was well managed with a median time in therapeutic range of 68.2% (interquartile range, 57.7%-77.7%). A sensitivity analysis using the modified intention-to-treat population during the on-treatment period identified a similar pattern for the primary efficacy end point of S/SE (data not shown).
A consistent pattern was also observed for the individual end point of ischemic stroke, which represented the majority of events in the primary composite end Trough blood samples were collected 1 month after randomization in 2725 subjects on treatment with the HDER. Creatinine clearance (CrCl; mL/min) at randomization was estimated with the Cockcroft-Gault equation.
point of S/SE (Table 2) . Although there was no significant effect modification of treatment efficacy with HDER versus warfarin by renal function subgroup (P for interaction=0.21), there was a trend toward decreased relative efficacy for ischemic stroke prevention in those with a CrCl >95 mL/min, with numerically higher rates in the HDER arm. Hemorrhagic stroke rates were consistently lower with HDER across the range of renal function compared with warfarin (P for interaction=0.59; Table 2 ). Cardiovascular death and all-cause mortality showed a nonsignificant trends toward decreased relative efficacy with HDER compared with warfarin with higher baseline CrCl (P for interaction for cardiovascular death=0.07; P for interaction for all-cause mortality=0.11; Table 2 ). Bleeding event rates were lowest in those with the highest CrCl (>95 mL/min; Figure 4B and Table 3 ). The relative risk of major bleeding was lower in patients treated with HDER compared with warfarin across the range of CrCl when assessed with the exploratory subgroups (P for interaction=0.11; Figure 4B and Table 3 ) and with CrCl as a continuous variable (P for interaction=0.35; Figure IIIB in the online-only Data Supplement). HDER The end points of (a) stroke or systemic embolism (S/SE); (B) International Society on Thrombosis and Haemostasis (ISTH) major bleeding; and (c) S/SE, major bleeding, or all-cause mortality are shown. Data for the efficacy and net clinical outcome analyses are from the intention-to-treat population for the overall study period. Data for safety are from the safety cohort for the treatment period with interval censoring of events during study-drug interruptions that lasted >3 days. CrCl (mL/min) at randomization was estimated with the Cockcroft-Gault equation. P for interaction for treatment by CrCl is shown for each end point. CI indicates confidence interval; HDER, higher-dose edoxaban regimen; and HR, hazard ratio. *HDER of 60 mg daily or 30 mg daily if dose-reduced for CrCl ≤50 mL/min, weight ≤60 kg, or potent phosphorylated glycoprotein inhibitor use.
showed a consistent safety profile for additional bleeding end points across the exploratory renal subgroups, including fatal, intracranial, and minor bleeding ( Table 3) . The relative risk of gastrointestinal bleeding was higher in those with moderate (CrCl 30-50 mL/min) or mild (CrCl >50-95 mL/min) renal dysfunction and lower in those with a CrCl >95 mL/min for HDER compared with warfarin (P for interaction=0.02; Table 3 ).
The primary net clinical outcome of S/SE, major bleeding, and all-cause death was more favorable for HDER compared with warfarin across the range of renal function subgroups (CrCl 30-50 mL/min; HR, 0.86; 95% CI, 0.75-0.98; CrCl >50-95 mL/min: HR, 0.91; 95% CI, 0.82-1.00; CrCl >95 mL/min: HR, 0.93; 95% CI, 0.77-1.13; P for interaction=0.73; Figure 4C and Table 2 ) and as a continuous variable ( Figure IIIC CI indicates confidence interval; CrCl, creatinine clearance at randomization; HDER, higher dose edoxaban regimen; HR, hazard ratio; LT, life-threatening; MI, myocardial infarction; and S/SE, stroke/systemic embolism. Data for efficacy and net clinical outcome analyses are from the intention-to-treat population for the overall study period. P for interaction is for the interaction of treatment and CrCl subgroup.
online-only Data Supplement). On the basis of a nonsignificant interaction across renal subgroups, findings were consistent with the overall trials results in which HDER was more favorable to warfarin for the secondary net clinical outcome of disabling stroke, life-threatening bleeding, or death (P for interaction=0. 19 ) and tertiary exploratory net clinical end points comprising severe or irreversible events (Table 2) . However, nonsignificant numerically higher rates were observed with HDER versus warfarin in those with a CrCl >95 mL/min for these secondary and tertiary net clinical end points (Table 2) . Similar findings were observed in a sensitivity analysis of net clinical benefit that compared rates of thromboembolism and intracranial hemorrhage, including a 1.5-fold higher impact weighting for intracranial hemorrhage (Table I in the online-only Data Supplement).
Outcomes by exploratory renal subgroups using the cKd-ePi Method
Application of the CKD-EPI method to estimate baseline renal function reclassified many patients into the mild renal dysfunction category, leaving only 6% of patients (n=749) with an estimated glomerular filtration rate >95 mL·min (Table II in the online-only Data Supplement). These subjects had relatively few baseline comorbidities (Table II in the online-only Data Supplement) and the lowest mean CHADS 2 (2.5±0.8), CHA 2 DS 2 -Vasc (3.2±1.1), and modified HAS-BLED (1.9±0.9) scores. Consequently, the annualized rates of S/SE were <1%/y in both arms, translating to very few events (n=5 for warfarin and n=9 for HDER; Figure IVA in the online-only Data Supplement). The relative risk of major bleeding was consistently lower across the exploratory subgroups using the CKD-EPI method (P for interaction=0.23; Figure  IVB in the online-only Data Supplement), and the primary net clinical outcome is as least as favorable across renal subgroups (P for interaction=0.56; Figure IVC in the online-only Data Supplement).
discussiOn
In this analysis of the ENGAGE AF-TIMI 48 study, we evaluated the impact of renal function on efficacy, safety, and net clinical outcomes in patients with AF at moderate to high risk of stroke treated with well-managed warfarin or edoxaban. Thromboembolic and bleeding event rates were lowest in those with the highest CrCl in all 3 treatment arms (warfarin, HDER, and LDER). In the prespecified renal subgroups defined by a CrCl of 30 to 50 and >50 mL/ min, findings were consistent with the overall trial results in which HDER was comparable to warfarin for the prevention of S/SE and resulted in significantly less major bleeding. However, exploratory analyses in patients with a CrCl >95 mL/min suggested lower relative efficacy for the prevention of thromboembolic events with HDER compared with warfarin. As a result of persistently lower rates of major bleeding in patients with a CrCl >95 mL/min, the primary net clinical outcome remained favorable for HDER compared with warfarin.
rationale for consideration of renal Function on Outcomes
Renal function, AF, and thromboembolic events are intimately related: Renal dysfunction is a risk factor for incident AF, which in turn is associated with progressive renal table 3. Bleeding end Points by exploratory crcl subgroups using the cockcroft-gault equation CI indicates confidence interval; CrCl, creatinine clearance at randomization; HDER, higher dose edoxaban regimen; HR, hazard ratio; and ISTH, International Society on Thrombosis and Haemostasis. P for interaction is for the interaction of treatment and CrCl subgroup. Data for safety are from the safety cohort for the treatment period with interval censoring of events during study-drug interruptions that lasted >3 days.
dysfunction. [12] [13] [14] Furthermore, in patients with AF, renal dysfunction is a risk factor for both thromboembolic and bleeding complications. [15] [16] [17] Therefore, it is important to understand whether renal function affects the safety and efficacy of the therapeutic options for the prevention of S/SE in patients with AF.
Warfarin is metabolized by the liver, primarily through CYP 2C9, and inactive metabolites are then excreted in the urine. Although warfarin elimination is therefore not governed by the kidneys, there is conflicting evidence from observational studies on the safety and efficacy of warfarin for AF in patients with chronic kidney disease. 18 In contrast, warfarin has been associated with a reduction in stroke compared with aspirin alone in patients with normal renal function. 19 All of the non-vitamin K antagonist oral anticoagulants (NOACs) undergo some degree of renal clearance. Dabigatran is the most renally cleared at 80%; edoxaban is renally cleared at 50%, rivaroxaban at 35% and apixaban at 27%. 20 On the basis of the premise that decreased renal clearance will result in higher drug levels, translating to an increased risk of bleeding, dose reduction is recommended for all of the NOACs in the setting of moderate to severe renal dysfunction. 3, 20, 21 In contrast, there has been less focus on NOAC efficacy in patients with normal renal function, in whom it could be hypothesized that normal or supranormal filtration may lead to suboptimal effective dosing and as a result suboptimal prevention of thromboembolism. It was in this framework that we sought to evaluate outcomes across the full range of baseline renal function with edoxaban and warfarin.
Outcomes across the range of renal Function
In this analysis, we found that the rates of S/SE and bleeding events were lowest in those with normal renal function (CrCl >95 mL/min) for all 3 arms of the ENGAGE AF-TIMI 48 trial (warfarin, HDER, and LDER). We found that in patients with moderate renal dysfunction (CrCl of 30-50 mL/min), HDER was comparable to warfarin for the prevention of S/SE and resulted in lower rates of major bleeding and a more favorable net clinical outcome. In the prespecified subgroup with mild or no renal dysfunction, defined by a CrCl >50 mL/min, the results were consistent with the overall trial population and those with moderate renal dysfunction. Exploratory analyses in patients with a CrCl >95 mL/min suggested lower relative efficacy for HDER compared with warfarin. Findings were consistent in sensitivity analyses of on-treatment S/ SE events and with a second method for estimating renal function, the CKD-EPI formula. This formula is believed to provide a more accurate estimation of glomerular filtration rate in patients with near-normal or normal renal function compared with the Cockcroft-Gault formula, which tends to overestimate renal function in this population. 9, 10 It is notable that the population with normal renal function (CrCl >95 mL/min by Cockcroft-Gault) had very low rates of S/SE of ≤1.1%/y in both treatment arms despite mean CHADS 2 and CHA 2 DS 2 -VASc scores of 2.6 and 3.5, respectively. In comparison, untreated patients with a CHA 2 DS 2 -VASc score of 3.5 would be predicted to have a stroke, transient ischemic attack, or systemic embolism rate of 3.3%/y to 5.3%/y in the Swedish Atrial Fibrillation cohort study. 22 
interpretation of the efficacy Findings
These findings support the use of HDER in AF patients with mild to moderate renal dysfunction (CrCl 30-95 mL/ min) based on comparable efficacy and superior safety to warfarin. This group represents a large proportion of patients with AF. The interpretation of the findings in patients with a CrCl >95 mL/min is more complicated and nuanced. As mentioned, the idea that excellent renal clearance may result in relatively subtherapeutic dosing and consequently less protection against stroke and lower bleeding rates is biologically plausible. This explanatory model is supported by 2 prior observations: Edoxaban plasma concentrations are associated with anti-factor Xa activity and outcomes, specifically major bleeding and S/SE, and pharmacokinetic studies demonstrated lower drug concentrations in patients with better renal function (CrCl >80 mL/min). 5, 23 In the present analysis, we observed a significant inverse relationship between edoxaban concentration and renal function, which would support the hypothesized mechanism for differential outcomes. It should be noted, however, that the range in concentrations for a given CrCl was large (data not shown), and as a result, there was substantial overlap in edoxaban concentrations across the range of renal functions. Furthermore, absolute edoxaban concentration thresholds that predict effective stroke prevention and an acceptable bleeding risk have not been defined.
The likelihood that this represents a genuine finding of decreased relative efficacy in the upper CrCl range with HDER is supported by consistent findings in patients with a CrCl >95 mL/min randomized to LDER. That is, patients with a CrCl >95 mL/min who received LDER, who would be hypothesized to have the lowest edoxaban drug levels, had the highest rates of S/SE (1.4%/y for LDER versus 1.1%/y for HDER versus 0.8%/y for warfarin) and lowest rates of major bleeding (1.1%/y for LDER versus 1.4%/y for HDER versus 2.3%/y for warfarin). The findings are further supported by the consistency of the on-treatment and CKD-EPI sensitivity analyses for the end point of S/SE and the mortality signal in those with a CrCl >95 mL/min with HDER versus warfarin.
renal Function and Other nOacs
As described above, all of the commercially available NOACs undergo some degree of renal elimination. However, even the most renally cleared agents have not been observed to have a statistically significant interaction for efficacy by renal function. Specifically, analyses of dabigatran (80% renally cleared) versus warfarin in the RE-LY trial (Randomized Evaluation of Long-term Anticoagulation Therapy) and apixaban (27% renally cleared) versus warfarin in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (AR-ISTOTLE) trial found no differential efficacy in subgroups defined by a CrCl ≤50, 50 to 80, and >80 mL/min. 24, 25 An analysis of rivaroxaban (35% renally cleared) versus warfarin in patients with normal renal function has not been published; however, no differential efficacy was observed comparing those with moderate (CrCl ≤50 mL/ min) and those with mild or no (>50 mL/min) renal dysfunction. 26 A meta-analysis of these data and data from the ENGAGE AF-TIMI 48 study found no significant effect modification by renal function for S/SE (P for interaction=0.12) or major bleeding (P for interaction=0.57).
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The lack of consistency of the findings described here for edoxaban with the other NOACs in patients with normal renal function may be explained by 1 or more of the following: The observed effect is agent-specific; chance played a role for 1 or both treatment arms in the analysis presented here; or the comparator (warfarin) performed particularly well in the ENGAGE AF-TIMI 48 study. We observed that patients with a CrCl >95 mL/ min are overall at very low risk of both thromboembolic and bleeding complications regardless of the anticoagulant chosen. Thus, the absolute number of S/SE events observed in the subgroup with a CrCl >95 mL/min is small, making it difficult to exclude the play of chance in either treatment arm. This is particularly notable in the warfarin-treated patients with a CrCl >95 mL/min who have an S/SE rate of 0.8%/y (n=35) by Cockcroft-Gault and 0.5%/y (n=5) by CKD-EPI. Additionally, the overall warfarin event rates in the ENGAGE AF-TIMI 48 trial are relatively low compared with the other NOAC trials in the setting of the highest time in therapeutic range and one of the highest mean CHADS 2 scores for the overall study population. 11, 24, 25 This observation has relevance when we consider the relative efficacy of a NOAC versus warfarin and may suggest that the findings described here could be due in part to excellent performance of warfarin in these patients.
implications of the efficacy Findings
On the basis of the limited data available at this time for edoxaban in patients with normal renal function (CrCl >95 mL/min), a definitive interpretation of the results is challenging. This fact is evidenced by the variation in the regulatory approval of edoxaban to date. The Cardiorenal Division of the US Food and Drug Administration reviewed the data from the ENGAGE AF-TIMI 48 study and recommended that edoxaban not be used in patients with a CrCl >95 mL/min for stroke prevention in AF. 3 This same restriction does not apply to warfarin or the other approved NOACs for which a similar signal was not observed. In contrast, the European Medicines Agency and the regulatory authorities of 3 Asian countries (Japan, Korea, and Taiwan) did not place any restrictions on the use of edoxaban in patients with normal renal function. Specifically, the European Medicines Agency cited the "exploratory nature of the subgroup analyses" and the "surprisingly low event rate with warfarin in patients with normal renal function." 27 The inconsistent interpretations of the findings with edoxaban point to a need for further investigation into the efficacy of renally cleared oral anticoagulants with a focus on those with normal renal clearance.
limitations
There are limitations to this analysis, several of which are described above. Additionally, beyond the prespecified subgroup analysis defined by a CrCl of 50 mL/min, all other analyses were exploratory; therefore, the findings should be considered hypothesis generating.
conclusions
Edoxaban demonstrated superior safety and comparable efficacy to warfarin for prevention of thromboembolic events in many patients with AF. However, for edoxaban and possibly other NOACs with significant renal clearance, the optimal dosing in the higher range of CrCl warrants further investigation.
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